mCureX Therapeutics
Main (gene editing) focus: Next-generation mRNA therapeutics
Company stage: Pre-clinical
Diseases: Genetic diseases, infectious diseases, cancer
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Website: https://www.mcurextx.com/en
Pipeline: https://www.mcurextx.com/en/rnd/pipeline
Location: Seongnam, Gyeonggi, South Korea
Partners: ToolGen
mCureX Therapeutics is a subsidiary of OliX Therapeutics. The company develops next-generation mRNA therapeutics and vaccines within different disease areas. In 2022, the company announced a collaboration with ToolGen to advance mRNA-based CRISPR-Cas9 gene editing to treat genetic eye diseases.